Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells

Journal of Experimental & Clinical Cancer Research

Paul B Tchounwou¹  Clement G Yedjou¹  Sanjay Kumar¹ 

[1] Cellomics and Toxicogenomics Research Laboratory, NIH/NIMHD-RCMI Center for Environmental Health, College of Science, Engineering and Technology, Jackson State University, 1400 Lunch Street, Box18750, Jackson, Mississippi MS39217, USA

关键词: HL-60 cells;    Apoptosis;    DNA damage;    Oxidative stress;    Arsenic trioxide;   

Others  :  802594
DOI  :  10.1186/1756-9966-33-42

 received in 2014-03-26, accepted in 2014-05-11,  发布年份 2014

【 摘 要 】

Background

Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML), which accounts for approximately 10% of all acute myloid leukemia cases. It is a blood cancer that is formed by chromosomal mutation. Each year in the United States, APL affects about 1,500 patients of all age groups and causes approximately 1.2% of cancer deaths. Arsenic trioxide (ATO) has been used successfully for treatment of APL patients, and both induction and consolidated therapy have resulted in complete remission. Recently published studies from our laboratory have demonstrated that ATO pharmacology as an anti-leukemic drug is associated with cytotoxic and genotoxic effects in leukemia cells.

Methods

In the present study, we further investigated the detailed molecular mechanism of ATO-mediated intrinsic pathway of apoptosis; using HL-60 cells as a test model. Oxidative stress was assessed by spectrophotometric measurements of MDA and GSH levels while genotoxicity was determined by single cell gel electrophoresis (Comet assay). Apoptosis pathway was analyzed by Western blot analysis of Bax, Bcl2 and caspase 3 expression, as well as immunocytochemistry and confocal imaging of Bax and Cyt c translocation and mitochondrial membrane potential depolarization.

Results

ATO significantly (p < 0.05) induces oxidative stress, DNA damage, and caspase 3 activityin HL-60 cells in a dose-dependent manner. It also activated the intrinsic pathway of apoptosis by significantly modulating (p < 0.05) the expression and translocation of apoptotic molecules and decreasing the mitochondrial membrane potential in leukemia cells.

Conclusion

Taken together, our research demonstrated that ATO induces mitochondrial pathway of apoptosis in HL-60 cells. This apoptotic signaling is modulated via oxidative stress, DNA damage, and change in mitochondrial membrane potential, translocation and upregulation of apoptotic proteins leading programmed cell death.

【 授权许可】

   
2014 Kumar et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Powell BL: Arsenic trioxide in acute promyelocytic leukemia: potion not poison. Expert Rev Anticancer Ther 2011, 11:1317-1319.
• [2]Jemal A, Thomas A, Murray T, Thun M: Cancer statistics. CA Cancer J Clin 2002, 52:23-47.
• [3]Yedjou C, Tchounwou P, Jenkins J, McMurray R: Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells. J Hematol Oncol 2010, 3:28-35. BioMed Central Full Text
• [4]Stone RM, Maguire M, Goldberg M: Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients. Blood 1988, 71:690-696.
• [5]Kantarjian HM, Keating MJ, Walters RS: Acute promyelocytic leukemia. M. D. Anderson Hospital experience. Am J Med 1986, 80:789-797.
• [6]Gallagher RE: Retinoic acid resistance in acute promyelocytic leukemia. Leukemia 2002, 16:1940-1958.
• [7]Soignet SL, Frankel SR, Douer D: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001, 19:3852-3860.
• [8]Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, et al.: Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013, 369:111-121.
• [9]Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP Jr: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998, 339:1341-1348.
• [10]Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, Hosseini R, Mossavi A, Baybordi E, Khodabadeh A, Iravani M, Bahar B, Mortazavi Y, Totonchi M, Aghdami N: Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 2006, 17:131-134.
• [11]Ghavamzadeh A, Alimoghaddam K, Rostami S, Ghaffari SH, Jahani M, Iravani M, Mousavi SA, Bahar B, Jalili M: Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol 2011, 29:2753-2757.
• [12]Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC, Kim BK, Lee YY: Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 2000, 60:3065-3071.
• [13]Soriano C, Creus A, Marcos R: Arsenic trioxide mutational spectrum analysis in the mouselymphoma assay. Mutat Res 2008, 646:1-7.
• [14]Patlolla AK, Tchounwou PB: Cytogenetic evaluation of arsenic trioxide toxicity in Sprague–Dawley rats. Mutat Res 2005, 587:126-133.
• [15]Stevens JJ, Graham B, Walker AM, Tchounwou PB, Rogers C: The effects of arsenic trioxideon DNA synthesis and genotoxicity in human colon cancer cells. Int J Environ Res Public Health 2010, 7:2018-2032.
• [16]Jiang XH, Wong BC, Yuen ST, Jiang SH, Cho CH, Lai KC, Lin MC, Kung HF, Lam SK: Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int J Cancer 2001, 91:173-179.
• [17]Tchounwou PB, Yedjou CG, Dorsey WC: Arsenic trioxide-induced transcriptional activation and expression of stress genes in human liver carcinoma cells (HepG2). Cell Mol Biol (Noisy-le-Grand) 2003, 49:1071-1079.
• [18]Alarifi S, Ali D, Alkahtani S, Siddiqui MA, Ali BA: Arsenic trioxide-mediated oxidative stress and genotoxicity in human hepatocellular carcinoma cells. Onco Targets Ther 2013, 6:75-84.
• [19]Wang ZG, Rivi R, Delva L, König A, Scheinberg DA, Gambacorti-Passerini C, Gabrilove JL, Warrell RP Jr, Pandolfi PP: Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PMLand PML-RARa independent manner. Blood 1998, 92:1497-1504.
• [20]Akao Y, Mizoguchi H, Kojima S, Naoe T, Ohishi N, Yagi K: Arsenic induces apoptosis in B-cell leukemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein. Br J Haematol 1998, 102:1055-1060.
• [21]Zhang W, Ohnishi K, Shigeno K, Fujisawa S, Naito K, Nakamura S, Takeshita K, Takeshita A, Ohno R: The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 1998, 12:1383-1391.
• [22]Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY, Chen Z: In vitro studies on cellular and molecular mechanisms of arsenic trioxide As2O3 in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with down-regulation of Bcl-2 expression and modulation of PML-RARa/PML proteins. Blood 1996, 88:1052-1061.
• [23]Cai X, Yu Y, Huang Y, Zhang L, Jia PM, Zhao Q, Chen Z, Tong JH, Dai W, Chen GQ: Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. Leukemia 2003, 17:1333-1337.
• [24]Collins SJ, Ruscetti FW, Gallagher RE, Gallo RC: Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci U S A 1978, 75:2458-2462.
• [25]Kumar S, Guha M, Choubey V, Maity P, Srivastava SK, Bandyopadhyay U: Bilirubin inhibits Plasmodium falciparum growth through the generation of reactive oxygen species. Free Radic Biol Med 2008, 44:602-613.
• [26]Singh NP, McCoy MT, Tice RR, Schneider EL: A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988, 175:184-191.
• [27]Yedjou CG, Tchounwou PB: In-vitro cytotoxic and genotoxic effects of arsenic trioxide on human leukemia (HL-60) cells using the MTT and alkaline single cell gel electrophoresis (Comet) assays. Mol Cell Biochem 2007, 301:123-130.
• [28]Velma V, Tchounwou PB: Oxidative stress and DNA damage induced by chromium in liver and kidney of goldfish, carassius auratus. Biomark Insights 2013, 8:43-51.
• [29]Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
• [30]Singh NK, Kundumani-Sridharan V, Kumar S, Verma SK, Kotla S, Mukai H, Heckle MR, Rao GN: Protein kinase N1 is a novel substrate of NFATc1-mediated cyclin D1-CDK6 activity and modulates vascular smooth muscle cell division and migration leading to inward blood vessel wall remodeling. J Biol Chem 2012, 287:36291-36304.
• [31]Wissing D, Mouritzen H, Jaattela M: TNF-induced mitochondrial changes and activation of apoptotic proteases are inhibited by A20. Free Radic Biol Med 1998, 25:57-65.
• [32]Cossarizza A, Baccarani-Contri M, Kalashnikova G, Franceschi C: A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the Jaggregate forming lipophilic cation 5,5_,6,6_-tetrachloro-1,1_,3,3_-tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochem Biophys Res Commun 1993, 197:40-45.
• [33]Guha M, Kumar S, Choubey V, Maity P, Bandyopadhyay U: Apoptosis in liver during malaria: role of oxidative stress and implication of mitochondrial pathway. FASEB J 2006, 20:1224-1226.
• [34]Chattopadhyay S, Fensterl V, Zhang Y, Veleeparambil M, Yamashita M, Sen GC: Role of interferon regulatory factor 3-mediated apoptosis in the establishment and maintenance of persistent infection by Sendai virus. J Virol 2013, 87:16-24.
• [35]Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB: Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 2000, 6:4957-4964.
• [36]Jang M, Kim Y, Won H, Lim S, KRJ , Dashdorj A, Min YH, Kim SY, Shokat KM, Ha J, Kim SS: Carbonyl reductase 1 offers a novel therapeutic target to enhance leukemia treatment by arsenic trioxide. Cancer Res 2012, 72:4214-4224.
• [37]Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL, Ma J, Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang ZY, de The H, Chen SJ, Chen Z: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997, 89:3345-3353.
• [38]Ma DC, Sun YH, Chang KZ, Ma XF, Huang SL, Bai YH, Kang J, Liu YG, Chu JJ: Selective induction of apoptosis of NB4 cells from G2 + M phase by sodium arsenite at lower doses. Eur J Haematol 1998, 61:27-35.
• [39]Baysan A, Yel L, Gollapudi S, Su H, Gupta S: Arsenic trioxide induces apoptosis via the mitochondrial pathway by upregulating the expression of Bax and Bim in human B cells. Int J Oncol 2007, 30:313-318.
• [40]Kang YH, Lee SJ: The role of p38 MAPK and JNK in arsenic trioxide-induced mitochondrial cell death in human cervical cancer cells. J Cell Physiol 2008, 217:23-33.
• [41]Catalani S, Carbonaro V, Palma F, Arshakyan M, Galati R, Nuvoli B, Battistelli S, Canestrari F, Benedetti S: Metabolism modifications and apoptosis induction after Cellfood™ administration to leukemia cell lines. J Exp Clin Cancer Res 2013, 32:63. BioMed Central Full Text
• [42]Niero EL, Machado-Santelli GM: Cinnamic acid induces apoptotic cell death and cytoskeleton disruption in human melanoma cells. J Exp Clin Cancer Res 2013, 32:31. BioMed Central Full Text
• [43]Huang Y, Hu J, Zheng J, Li J, Wei T, Zheng Z, Chen Y: Down-regulation of the PI3K/Akt signaling pathway and induction of apoptosis in CA46 Burkitt lymphoma cells by baicalin. J Exp Clin Cancer Res 2012, 31:48. BioMed Central Full Text
• [44]Okui T, Fujiwara Y: Inhibition of human excision DNA repair by inorganic arsenic and the comutageniceffect in V79 Chinese hamster cells. Mutat Res 1986, 172:69-76.
• [45]Kryeziu K, Jungwirth U, Hoda MA, Ferk F, Knasmüller S, Karnthaler-Benbakka C, Kowol CR, Berger W, Heffeter P: Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair. Mol Cancer Ther 2013, 12:1073-1084.
• [46]Kessel M, Liu SX, Xu A, Santella R, Hei TK: Arsenic induces oxidative DNA damage in mammalian cells. Mol Cell Biochem 2002, 234–235:301-308.
• [47]Ninomiya M, Kajiguchi T, Yamamoto K, Kinoshita T, Emi N, Naoe T: Increased oxidative DNA products in patients with acutepromyelocyticleukemia during arsenic therapy. Haematologica 2006, 91:1571-1572.
• [48]Jia P, Chen G, Huang X, Cai X, Yang J, Wang L, Zhou Y, Shen Y, Zhou L, Yu Y, Chen S, Zhang X, Wang Z: Arsenic trioxide induces multiple myeloma cell apoptosis via disruption of mitochondrial transmembrane potentials and activation of caspace-3. Chin Med J (Engl) 2001, 114:19-24.
• [49]Lu M, Levin J, Sulpice E, Sequeira-Le Grand A, Alemany M, Caen JP, Han ZC: Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines. Exp Hematol 1999, 27:845-852.
• [50]Rousselot P, Labaume S, Marolleau JP, Larghero J, Noguera MK, Brouet JC, Fermand JP: Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cellsfrom myeloma patients. Cancer Res 1999, 59:1041-1048.
• [51]Carvalho PS, Catian R, Moukha S, Matias WG, Creppy EE: Comparative study of domoic acid and okadaic acid induced -chromosomal abnormalities in the CACO-2 Cell Line. Int J Environ Res Public Health 2006, 3:4-10.